Edgewise Therapeutics, Inc. (EWTX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial.
Is Edgewise Therapeutics, Inc. stock overvalued or undervalued in 2026?
Edgewise Therapeutics, Inc. (EWTX) trades at 4.7× earnings (P/E). No valuation verdict: it trades at 4.7 times its 12-month earnings, but there is not enough data to compare it with.
Kaplio overview: Edgewise Therapeutics, Inc.
Market cap $4B · 52 weeks $17 – $48 (20% below the high) · P/E 4.7× · Dividend none · Next earnings February 25, 2027 · expected EPS -$0.53 · Closing price, Nov 5 · accounts published Nov 4.
- Balance sheet: Safe zone (solid).
- Earnings: 5 of 8 (uneven).
Where would it trade at its usual multiples?
No valuation verdict: it trades at 4.7 times its 12-month earnings, but there is not enough data to compare it with.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 0.0%, fails.
- Market cap / Cash 7.5×, fails.
- Cash Runway 44 months, passes.
- Total Debt 0.0×, passes.
- Annual cash burn $1.40, info.
Against its peers (reference peers) — Edgewise Therapeutics, Inc.: P/E 4.8×; EV/EBITDA 3.5×; ROIC -11.6%; $4.2B. PTC Therapeutics, Inc. (P/E —; EV/EBITDA 33.8×; ROIC 5.7%; $5.5B), Acadia Pharmaceuticals Inc. (P/E 10.1×; EV/EBITDA 18.4×; ROIC 8.4%; $3.7B), Arcutis Biotherapeutics, Inc. (P/E 127×; EV/EBITDA 77.5×; ROIC 9.5%; $3.4B).
Profitability
| Return on Equity | 130.43% |
| Return on Invested Capital | -11.55% |
| Return on Assets | 56.72% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 12.30 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 49.11 |
Price Performance
| 1 month | -1.77% |
| 3 months | -10.68% |
| Year-to-date | +56.61% |
| 1 year | +127.44% |
| 3 years | +518.95% |
| 5 years | +95.33% |
Related companies: PTCT · DYN · VRTX · 0QZU.L · MRNA · REGN · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of EWTX: Financials · Valuation · Estimates · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks